Non-small Cell Lung Cancer
Conditions
Keywords
Oncology, Sutetinib Maleate Capsule, Teligene, Cancer
Brief summary
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Detailed description
Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor. EGFR is a gene that makes a protein that is involved in cell growth and cell survival. Mutated (changed) forms of the EGFR gene and protein have been found in some types of cancer, including non-small cell lung cancer. These changes may cause cancer cells to grow and spread in the body. The purpose of this study is to explore how effective sutetinib maleate capsules are for the treatment of patients with locally advanced or metastatic NSCLC with uncommon EGFR mutations.
Interventions
Oral administration
Sponsors
Teligene US
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years old and above, male or female 2. Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC 3. Confirmation that the tumor harbors an uncommon epidermal growth factor receptor (EGFR) mutation (tumor tissue biopsy) 4. At least one measurable lesion 5. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 6. A minimum life expectancy of \> 3 months 7. Adequate bone marrow reserve, hepatic, renal, and coagulation function Other inclusion criteria apply for participating in the study.
Exclusion criteria
1. Participant ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) for anti-tumor therapy prior to enrollment (Cohort 1), or second generation EGFR TKI (Cohort 2) 2. Any systemic anti-tumor therapy such as chemotherapy and radiation therapy (including curative radiotherapy or spinal radiotherapy portion \>30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for the tumor within 2 weeks prior to enrollment; Cohort 2: any EGFR TKIs within 5 half-lives. 3. Use or intake of drugs or foods containing potent inhibitors or inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever is the longer, prior to enrollment 4. Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment 5. Any unresolved toxicities from prior therapy greater than National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAEv5.0) Grade 1, at the time of screening except for alopecia 6. Inability to swallow the study medication, any seriously (NCI-CTCAEv5.0 ≥ Grade 3) chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption 7. Active central nervous system metastases 8. Any active infection which has not been controlled at screening Other
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | Pre-dose up to approximately 32 months post-dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DoR) | Pre-dose up to approximately 32 months post-dose | — |
| Disease Control Rate (DCR) | Pre-dose up to approximately 32 months post-dose | — |
| Progression Free Survival (PFS) | Pre-dose up to approximately 32 months post-dose | — |
| Time to Tumor Progression (TTP) | Pre-dose up to approximately 32 months post-dose | — |
| Time to Response (TTR) | Pre-dose up to approximately 32 months post-dose | — |
| Time to Treatment Failure (TTF) | Pre-dose up to approximately 32 months post-dose | — |
| Overall Survival (OS) | Pre-dose up to approximately 32 months post-dose | — |
| 1-year Progression Free Survival | Pre-dose up to 1 year post-dose | Ratio of participants who do not have objective tumor progression or have not died 1 year after the first dose of IP. |
| 1-year Survival | Pre-dose up to 1 year post-dose | Ratio of surviving participants 1 year after the first dose of IP. |
| Area Under The Curve (AUC) of Sutetinib Maleate Capsule | Pre-dose up to 24 hours post-dose | — |
| Maximum Plasma Concentration (Cmax) of Sutetinib Maleate Capsule | Pre-dose up to 24 hours post-dose | — |
| Minimum Plasma Concentration (Cmin) of Sutetinib Maleate Capsule | Pre-dose up to 24 hours post-dose | — |
| Time to Peak Drug Concentration (Tmax) of Sutetinib Maleate Capsule | Pre-dose up to 24 hours post-dose | — |
| Sutetinib Maleate Capsule half-life (T1/2) | Pre-dose up to 24 hours post-dose | — |
| Apparent Clearance (CL/f) of Sutetinib Maleate Capsule | Pre-dose up to 24 hours post-dose | — |
| Volume of Distribution (Vz/F) of Sutetinib Maleate Capsule | Pre-dose up to 24 hours post-dose | — |
| Number of Participants Experiencing Adverse Events (AE) | Pre-dose up to approximately 32 months post-dose | — |
| Number of Participants Experiencing Adverse Drug Reactions (ADR) | Pre-dose up to approximately 32 months post-dose | — |
| Number of Participants Experiencing Serious Adverse Events (SAE) | Pre-dose up to approximately 32 months post-dose | — |
| Number of Participants Experiencing Srious Adverse Reactions (SAR) | Pre-dose up to approximately 32 months post-dose | — |
Countries
United States
Contacts
CONTACTXiaoyang Xia
CONTACTDawei Zhang
Outcome results
None listed